La tuberculose . Durée du traitement

Translated title of the contribution: Short-course chemotherapy of tuberculosis

J. Grosset

Research output: Contribution to journalArticle

Abstract

The systematic use of rifampicin (R) and pyrazinamide (Z) in combination with isoniazid (H) and ethambutol (E) has resulted in a dramatic shortening of the duration of chemotherapy for tuberculosis, since the time when H, streptomycin (S) and PAS (P) were given for 18 to 24 months. Short-course chemotherapy of 6-month duration with the four drugs combination, SHRZ or EHRZ, given for a 2-month initial intensive phase followed by a 4-month continuation phase with HR is as effective and acceptable as the standard 9-month chemotherapy with EHR for the treatment of smear-positive pulmonary tuberculosis. The length of chemotherapy can be reduced neither for smear-negative culture-positive nor for smear-negative culture negative pulmonary tuberculosis nor for extra-pulmonary tuberculosis. Isoniazid has been demonstrated to be active as chemoprophylactic drug in a daily dose of 300 mg (5 - 10 mg/kg children for 6-12 months. Chemoprophilaxis with daily isonazid, rifampicin and pyrazinamide for 2 months is likely to be as active as isoniazid prophylaxis for 12 months.

Original languageFrench
Pages (from-to)795-798
Number of pages4
JournalMedecine et Maladies Infectieuses
Volume17
Issue number12 PART 2
StatePublished - Dec 1987
Externally publishedYes

Fingerprint

Isoniazid
Tuberculosis
Pulmonary Tuberculosis
Pyrazinamide
Drug Therapy
Rifampin
Ethambutol
Streptomycin
Drug Combinations
Pharmaceutical Preparations
Therapeutics

Keywords

  • Chemotherapy of tuberculosis
  • Short-course chemotherapy
  • Tuberculosis

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Grosset, J. (1987). La tuberculose . Durée du traitement. Medecine et Maladies Infectieuses, 17(12 PART 2), 795-798.

La tuberculose . Durée du traitement. / Grosset, J.

In: Medecine et Maladies Infectieuses, Vol. 17, No. 12 PART 2, 12.1987, p. 795-798.

Research output: Contribution to journalArticle

Grosset, J 1987, 'La tuberculose . Durée du traitement', Medecine et Maladies Infectieuses, vol. 17, no. 12 PART 2, pp. 795-798.
Grosset, J. / La tuberculose . Durée du traitement. In: Medecine et Maladies Infectieuses. 1987 ; Vol. 17, No. 12 PART 2. pp. 795-798.
@article{d1a097f5b3d2434db549aa34083e4cfd,
title = "La tuberculose . Dur{\'e}e du traitement",
abstract = "The systematic use of rifampicin (R) and pyrazinamide (Z) in combination with isoniazid (H) and ethambutol (E) has resulted in a dramatic shortening of the duration of chemotherapy for tuberculosis, since the time when H, streptomycin (S) and PAS (P) were given for 18 to 24 months. Short-course chemotherapy of 6-month duration with the four drugs combination, SHRZ or EHRZ, given for a 2-month initial intensive phase followed by a 4-month continuation phase with HR is as effective and acceptable as the standard 9-month chemotherapy with EHR for the treatment of smear-positive pulmonary tuberculosis. The length of chemotherapy can be reduced neither for smear-negative culture-positive nor for smear-negative culture negative pulmonary tuberculosis nor for extra-pulmonary tuberculosis. Isoniazid has been demonstrated to be active as chemoprophylactic drug in a daily dose of 300 mg (5 - 10 mg/kg children for 6-12 months. Chemoprophilaxis with daily isonazid, rifampicin and pyrazinamide for 2 months is likely to be as active as isoniazid prophylaxis for 12 months.",
keywords = "Chemotherapy of tuberculosis, Short-course chemotherapy, Tuberculosis",
author = "J. Grosset",
year = "1987",
month = "12",
language = "French",
volume = "17",
pages = "795--798",
journal = "Medecine et Maladies Infectieuses",
issn = "0399-077X",
publisher = "Elsevier Masson",
number = "12 PART 2",

}

TY - JOUR

T1 - La tuberculose . Durée du traitement

AU - Grosset, J.

PY - 1987/12

Y1 - 1987/12

N2 - The systematic use of rifampicin (R) and pyrazinamide (Z) in combination with isoniazid (H) and ethambutol (E) has resulted in a dramatic shortening of the duration of chemotherapy for tuberculosis, since the time when H, streptomycin (S) and PAS (P) were given for 18 to 24 months. Short-course chemotherapy of 6-month duration with the four drugs combination, SHRZ or EHRZ, given for a 2-month initial intensive phase followed by a 4-month continuation phase with HR is as effective and acceptable as the standard 9-month chemotherapy with EHR for the treatment of smear-positive pulmonary tuberculosis. The length of chemotherapy can be reduced neither for smear-negative culture-positive nor for smear-negative culture negative pulmonary tuberculosis nor for extra-pulmonary tuberculosis. Isoniazid has been demonstrated to be active as chemoprophylactic drug in a daily dose of 300 mg (5 - 10 mg/kg children for 6-12 months. Chemoprophilaxis with daily isonazid, rifampicin and pyrazinamide for 2 months is likely to be as active as isoniazid prophylaxis for 12 months.

AB - The systematic use of rifampicin (R) and pyrazinamide (Z) in combination with isoniazid (H) and ethambutol (E) has resulted in a dramatic shortening of the duration of chemotherapy for tuberculosis, since the time when H, streptomycin (S) and PAS (P) were given for 18 to 24 months. Short-course chemotherapy of 6-month duration with the four drugs combination, SHRZ or EHRZ, given for a 2-month initial intensive phase followed by a 4-month continuation phase with HR is as effective and acceptable as the standard 9-month chemotherapy with EHR for the treatment of smear-positive pulmonary tuberculosis. The length of chemotherapy can be reduced neither for smear-negative culture-positive nor for smear-negative culture negative pulmonary tuberculosis nor for extra-pulmonary tuberculosis. Isoniazid has been demonstrated to be active as chemoprophylactic drug in a daily dose of 300 mg (5 - 10 mg/kg children for 6-12 months. Chemoprophilaxis with daily isonazid, rifampicin and pyrazinamide for 2 months is likely to be as active as isoniazid prophylaxis for 12 months.

KW - Chemotherapy of tuberculosis

KW - Short-course chemotherapy

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=0023583022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023583022&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0023583022

VL - 17

SP - 795

EP - 798

JO - Medecine et Maladies Infectieuses

JF - Medecine et Maladies Infectieuses

SN - 0399-077X

IS - 12 PART 2

ER -